2016-09-15 12:17:15 UTC

Future Biomarkers to Assess IBD Activity

Sept. 15, 2016

On-demand recording: Dr. David T. Rubin discusses current and future biomarkers for IBD, and also new tools that could help IBD patients.

Select presentations from the 2016 AGA Tech Summit are now available in the Education section of the AGA website. One you won’t want to miss: David T. Rubin, MD, AGAF, discussing future biomarkers to assess IBD disease activity. During his presentation, he provides a framework for biomarkers in IBD, discussing:

  • Currently available biomarkers in IBD.
  • New tools of interest for IBD patients.
  • The utility of serologies and genetic markers.
  • Future directions in therapeutic drug monitoring.

Watch below, or check out other recordings from the AGA Tech Summit or AGA’s IBD on-demand resources.

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.

Get Your Questions Answered on Biosimilar Therapies

Dec. 7, 2017

Join inflammatory bowel disease (IBD) experts on Dec. 11, 2017, 8-8:45 p.m. ET, for a free webinar on biosimilar therapies.